Results 201 to 210 of about 3,564,396 (291)
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Using Blackboard to Deliver Library Research Skills Assessment: A Case Study
Maura A. Smale, Mariana Regalado
openalex +2 more sources
Discussion of “River-Ice Problems: A State-of-the-Art Survey and Assessment of Research Needs” [PDF]
Charles R. Neill
openalex +1 more source
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Research assessment - still opera in theatres. [PDF]
Jones AR.
europepmc +1 more source
Impact assessment of IFPRI's research and related activities based on economywide modeling
Kym Anderson, Anderson, Kym
openalex +2 more sources
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Past suicide attempts in depressed inpatients: clinical versus research assessment. [PDF]
Molero P +9 more
europepmc +1 more source
RESEARCH OF RISK ASSESSMENT PROBLEM OF CONVERGENCE TRAJECTORIES OF THE TWO DYNAMIC OBJECTS
Alexander Goloskokov, Mykhailo Brodskyi
openalex +2 more sources
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source

